House Tries To Rein In Pharmaceutical Ads

Lawmakers in the House have declared war on drug ads. One bill would ban ads for prescription sexual aids like Viagra and Levitra from prime-time television. The New York Times reports another bill would end a drug company's ability to write off the cost of their TV ads as a business expense.

Copyright © 2009 NPR. For personal, noncommercial use only. See Terms of Use. For other uses, prior permission required.

STEVE INSKEEP, host:

NPR's business news starts with efforts to block TV drug ads.

(Soundbite of music)

Some house lawmakers are trying to rein in pharmaceutical commercials aimed at consumers. According to The New York Times, one such bill would ban ads for prescription aids like Viagra. Another would end drug company's ability to write off the cost of their TV ads as a business expense.

Critics say these ads encourage people to demand pricy brand name drugs, driving up the cost of health care. The Times cites a study indicating these ads can, though, help people who need treatment start taking proper drugs.

Copyright © 2009 NPR. All rights reserved. No quotes from the materials contained herein may be used in any media without attribution to NPR. This transcript is provided for personal, noncommercial use only, pursuant to our Terms of Use. Any other use requires NPR's prior permission. Visit our permissions page for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR's programming is the audio.

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

Support comes from: